Pharmacy Drugs
Recent Posts
- Lytix Biopharma AS Announces Regulatory Approval By Norwegian And Swedish Authorities To Commence Phase I Clinical Trial Of OncoporeTM In Cancer
- NPA Responds To Quality Accounts Consultation, UK
- Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing “Revolutionary” Phase III Study Results
- Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
- PHT Corporation’s Market Leading LogPad And StudyWorksTM EPRO Solutions Used In Sanofi Pasteur’s Phase II Study Of New Clostridium Difficile Vaccine
Random Posts
- Alcon Commences Phase 2 Clinical Trial Of NovaBay's NVC-422 For Viral Conjunctivitis
- FDA Likely to Approve H1N1 Vaccine In Advance of Data
- Industry Asked To Fund Government Purchasing, Australia
- Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency
- Chlamydia Service Training For Support Staff - A Success! UK
- Pirfenidone May Help Lung Function In IPF Patients According To Large Clinical Trial
- Developments In Wound Management To Revolutionise Traditional Practices, UK
- LAM Patients Participate In Clinical Trials To Help Others, Not Themselves, Study Shows
- St. Jude Medical Announces Leading Sponsorship Of Landmark Clinical Trial To Study Atrial Fibrillation
- New Study Shows Coaching To Patient Activation Levels Improves Disease Management Outcomes
BioElectronics Announces Pivotal Clinical Study On Musculoskeletal Disorders
Posted by: admin in Pharmacy Drugs on September 22nd, 2009
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced its sponsorship of a groundbreaking clinical study on musculoskeletal disorders. The randomized, double blinded and placebo-controlled study will be supervised by a primary investigator, Sheena Kong, MD of San Francisco, California in conjunction with several other leading physicians.
“This is a very exciting field of research and we are looking forward to determining the safety and efficacy of BioElectronics Corporation’s ActiPatch for the treatment of many different types of musculoskeletal complaints,” commented Dr. Kong. “Since my days studying at Harvard University I have been very interested in treatments such as Pulsed Electromagnetic Field therapy (PEMF) as an alternative to pharmaceuticals. We are currently in process of working with our Independent Review Board (IRB) and registering the study with the National Institutes of Health (NIH). Patient recruitment is expected to begin over the next few weeks. We believe this will be one of the largest studies ever completed on the subject of general muscular skeletal complaints.”
Andrew Whelan, CEO of BioElectronics Corp., added, “The sponsorship and completion of the study are significant events for our Company. While we are seeing success within the plastic surgery market and in our international distribution channels, we believe the U.S. markets for back, knee, foot/ankle, and elbow pain are our biggest opportunities. This study is specifically designed to allow us to apply to the U.S. Food and Drug Administration for an indication for pain relief for general muscular skeletal complaints. With the many concerns over the dangers of taking medications such as acetaminophen and NSAIDs, we believe U.S. consumers are looking for safer and more effective pain relief options. We believe our unique and patented drug-free technologies will effectively fill this need.”
The management team of BioElectronics will hold a conference call on Thursday, June 18 at 4:15 p.m. (EDT) to discuss this study and other ongoing clinical trials several of which are nearing conclusion. On the call Barry Eppley, M.D., D.M.D will discuss the recent clinical study on dysmenorrhea and Sheena Kong, MD will discuss the design of the musculoskeletal disorder study. To access the conference call, please dial 712-432-0080 approximately 10 minutes prior to the start time and enter access code 404367# to be placed into the conference.
Source
BioElectronics Corporation
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.